Related Experiment Video
Updated: Feb 4, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo
Backgrounds/Aims:
Bromodomain-containing protein 4 (BRD4) overexpression participates in prostate cancer progression by enhancing the transcriptional activity and expression of several key oncogenes. AZD5153 is a novel BRD4 inhibitor.
Methods:
Prostate cancer cells were treated with AZD5153. Cell survival was tested by MTT assay and clonogenicity assay. Cell proliferation was tested by [H3] DNA incorporation assay. Cell apoptosis was tested by caspase-3/-9 activity assay, Histone DNA ELISA assay, Annexin V FACS assay and TUNEL staining assay. Cell cycle progression was tested by propidium iodide (PI) FACS assay. Signaling was tested by Western blotting assay. The nude mice PC-3 xenograft model was applied to test AZD5153's activity in vivo.
Results:
AZD5153 inhibited proliferation and survival of established and primary prostate cancer cells. AZD5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. AZD5153 was non-cytotoxic to the prostate epithelial cells. AZD5153 downregulated BRD4 targets (cyclin D1, Myc, Bcl-2, FOSL1 and CDK4) in PC-3 and primary prostate cancer cells. Further studies show that AKT could be the primary resistance factor of AZD5153. Pharmacological inhibition or genetic depletion of AKT induced BRD4 downregulation, sensitizing AZD5153-induced cytotoxicity in PC-3 cells. In vivo, AZD5153 oral administration inhibited PC-3 xenograft tumor growth in nude mice. Its anti-tumor activity was further enhanced with co-treatment of the AKT specific inhibitor MK-2206.
Conclusion:
Together, our results indicate a promising therapeutic value of the novel BRD4 inhibitor AZD5153 against prostate cancer cells.
Insights
The novel bromodomain-containing protein 4 (BRD4) inhibitor AZD5153 effectively reduced prostate cancer cell proliferation and survival. Combination therapy with an AKT inhibitor enhanced AZD5153
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Bromodomain-containing protein 4 (BRD4) overexpression drives prostate cancer progression by upregulating oncogenes.
- AZD5153 is a novel inhibitor targeting BRD4.
Purpose of the Study:
- To evaluate the therapeutic potential of AZD5153 in prostate cancer.
- To investigate the mechanisms underlying AZD5153's efficacy and resistance.
Main Methods:
- In vitro studies utilized prostate cancer cell lines treated with AZD5153, assessing survival, proliferation, apoptosis, cell cycle, and signaling pathways.
- In vivo efficacy was tested using a PC-3 xenograft model in nude mice.
- AKT's role as a resistance factor was investigated through inhibition and depletion studies.
Main Results:
- AZD5153 inhibited prostate cancer cell proliferation and survival, inducing apoptosis and cell cycle arrest.
- The drug downregulated key BRD4 targets, including cyclin D1, Myc, Bcl-2, FOSL1, and CDK4.
- AKT was identified as a resistance factor; its inhibition sensitized cells to AZD5153 and enhanced anti-tumor activity in vivo when combined with MK-2206.
Conclusions:
- AZD5153 demonstrates significant anti-prostate cancer activity by targeting BRD4.
- Combining AZD5153 with AKT inhibitors like MK-2206 may represent a potent therapeutic strategy for prostate cancer.
More Related Videos
Related Concept Videos
Feedback Inhibition
Equivalence: In Vitro and In Vivo Bioequivalence
Enzyme Inhibition
Cells Coordinate Growth and Proliferation
Primary and Secondary Growth in Roots and Shoots
Population Growth

